In the face of a global crisis, Novartis has quickly mobilized R&D capabilities, medicines, clinical trials expertise and philanthropic aid to ...
Inside the hunt for new antivirals to combat the current pandemic and to prepare for future ones.
Oct 01, 2021
May 27, 2021
May 06, 2021
April 16, 2021
In this podcast, Novartis CEO Vas Narasimhan and Sal Khan discuss about modern day breakthroughs in the world of medicine and what we can expect for the future of health as we emerge from COVID-19.
Novartis CEO Vas Narasimhan discusses how to improve pandemic preparedness at the CNBC Evolve Global Summit.
An interview with Dr Steffen Lang, Global Head of Novartis Technical Operations on how Novartis is involved in manufacturing COVID-19 vaccines.
The coronavirus crisis has not only challenged the medical community to seek new treatments and vaccines. Keeping up with the production of ...
Novartis is working to ensure supply of our medicines, enhance virtual services, protect the integrity of clinical trials and support patient organizations during the coronavirus disease (COVID-19) pandemic.
Novartis is working closely with healthcare professionals during the coronavirus disease pandemic. We are embracing new ways of working and have rapidly scaled up multichannel engagement.
Novartis is regularly updating our Investor and Shareholder communities on the impact of coronavirus disease (COVID-19) and our response.
Novartis is supporting candidates during the coronavirus disease (COVID-19) outbreak. During this time interviews will continue as planned and, where appropriate, will be switched to virtual interviews using readily available technology.
Novartis is providing suppliers with recommended good practices guidance during the coronavirus disease (COVID-19) pandemic based on the most up-to-date World Health Organization (WHO) technical information.
Novartis provides country-specific information about coronavirus disease (COVID-19) in local languages.
Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19.
Novartis has joined the accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome and Mastercard.
Novartis is supporting Conquer Cancer, the ASCO Foundation to allow for better understanding of COVID-19 in cancer care.
Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative.
Novartis is part of a consortium engaging with the Innovative Medicines Initiative (IMI) on their COVID-19 directed efforts.
Novartis is making available several compounds from our libraries that are considered suitable for in vitro antiviral testing.
CDC coronavirus disease (COVID-19) resources
COVID-19 online hub